key: cord-0880161-3pqabfvb
authors: Pilotto, Andrea; Masciocchi, Stefano; Volonghi, Irene; Crabbio, Massimo; Magni, Eugenio; De Giuli, Valeria; Caprioli, Francesca; Rifino, Nicola; Sessa, Maria; Gennuso, Michele; Cotelli, Maria Sofia; Turla, Marinella; Balducci, Ubaldo; Mariotto, Sara; Ferrari, Sergio; Ciccone, Alfonso; Fiacco, Fabrizio; Imarisio, Alberto; Risi, Barbara; Benussi, Alberto; Premi, Enrico; Focà, Emanuele; Caccuri, Francesca; Leonardi, Matilde; Gasparotti, Roberto; Castelli, Francesco; Zanusso, Gianluigi; Pezzini, Alessandro; Padovani, Alessandro
title: Clinical presentation and outcomes of SARS-CoV-2 related encephalitis: the ENCOVID multicentre study
date: 2020-09-28
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa609
sha: c4692ade3c95a1cb3ce449bc7d240b2a964cd947
doc_id: 880161
cord_uid: 3pqabfvb

BACKGROUND: Several preclinical and clinical investigations have argued for nervous system involvement in SARS-CoV-2 infection. Some sparse case reports have described various forms of encephalitis in COVID-19 disease, but very few data have focused on clinical presentations, clinical course, response to treatment and outcomes. METHODS: The ENCOVID multicentre study included patients with encephalitis with full infectious screening, CSF, EEG, MRI data and confirmed SARS-CoV-2 infection recruited from 13 centres in northern Italy. Clinical presentation and laboratory markers, severity of COVID-19 disease, response to treatment and outcomes were recorded. RESULTS: twenty-five cases of encephalitis positive for SARS-CoV-2 infection were included. CSF showed hyperproteinorrachia and/or pleocytosis in 68% of cases whereas SARS-CoV-2 RNA by RT-PCR resulted negative. Based on MRI, cases were classified as ADEM (n=3), limbic encephalitis (LE, n=2), encephalitis with normal imaging (n=13) and encephalitis with MRI alterations (n=7). ADEM and LE cases showed a delayed onset compared to the other encephalitis (p=0.001) and were associated with previous more severe COVID-19 respiratory involvement. Patients with MRI alterations exhibited worse response to treatment and final outcomes compared to other encephalitis. CONCLUSIONS: SARS-CoV-2 infection is associated with a wide spectrum of encephalitis characterized by different clinical presentation, response to treatment and outcomes.

SARS-CoV-2 infection is mainly characterized by respiratory tract symptoms with adverse outcomes mostly related to the severity of acute respiratory distress syndrome (ARDS). With the increasing number of confirmed cases and the accumulating clinical data, it is now well established that, in addition to the predominant respiratory symptoms, a significant proportion of COVID-19 patients experience neurological symptoms, including olfactory dysfunction, [1] headache and confusion. [2, 3] SARS-CoV-2 infection has also the potential for specifically targeting the central nervous system (CNS) and some cases of encephalitis have been described in patients admitted to intensive care unit for severe respiratory distress. [4, 5] Few case reports also described the occurrence of encephalitis during SARS-CoV-2 infection independently from ARDS, arguing for a CNS inflammatory-mediated involvement. [6, 7] However, the neurotropism of SARS-CoV-2 infection and the mechanisms leading to specific brain involvement are still theme of debate. [8] [9] [10] In fact, literature findings have been limited to few single-centre series while a full work-up for alternative causes of brain infections was often not performed. [11] In order to investigate the relationship between COVID-19 and CNS involvement, a network was established involving 13 neurological units in Lombardy and Veneto, covering an area with the highest number of COVID-19 cases observed in Italy so far. [12] The aim of the study was to identify all cases of encephalitis associated with SARS-CoV-2 infection, to analyse their relationship with respiratory function and inflammatory parameters and to describe their clinical, laboratory and neuroimaging findings, the clinical course and response to treatment.

A c c e p t e d M a n u s c r i p t 6 METHODS:

Data were collected in the setting of a multicentre, ongoing, hospital-based, longitudinal cohort study on encephalitis during the COVID-19 pandemic (ENCOVID-study). All patients consecutively admitted to the participating hospitals between February 20 th and May 31 st 2020, with symptoms suggestive of encephalitis were screened for inclusion. The case definition included any person aged 18 admitted to hospital with altered mental status (defined as decreased or altered level of consciousness, lethargy or personality changes) lasting ≥24 hours and the presence of two or more of the following criteria [13] : i) generalized or partial seizures not fully attributable to a pre-existing epilepsy ii) new onset of focal neurologic findings iii) CSF white blood cell count ≥5/cubic mm 3 iv) abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that was either new from prior studies or appears acute in onset v) abnormality on electroencephalography consistent with encephalitis and not attributable to another cause. Fever was not considered as supportive feature for encephalitis (as indicated by standard criteria [13] ), as it is highly prevalent in COVID-19 disease. [14] . Stroke and hemorrhages at MRI were listed as exclusion criteria.

Demographic information, clinical manifestations, laboratory findings, EEG, neuroimaging, treatment and outcomes were extracted from medical records using a standardized anonymized data collection form by study physicians and checked by senior investigators at each centre.

The Institutional Ethical Standards Committee on human experimentation at Brescia University Hospital provided approval for the study (NP 4067, approved May 8 th , 2020).

A c c e p t e d M a n u s c r i p t 7

Laboratory confirmation of SARS-CoV-2 infection was carried out by RT PCR procedure on throatswab and nasopharyngeal specimens in all patients. In case of high clinical suspicion of SARS-CoV-2 infection and negative test results on nasopharyngeal and oropharyngeal swabs, testing of lower respiratory samples (bronchoalveolar lavage fluid obtained by bronchoscopy) was performed. In all patients, routine blood examinations included complete blood count, coagulation profile, serum biochemical tests, including renal and liver function and lactate dehydrogenase. The illness severity of COVID-19 was defined according to the Brescia COVID Respiratory Severity Scale (BCRSS) for COVID-19 [15] and according to the quick Sequential Organ Failure Assessment (qSOFA). [14] Respiratory function at admission, during hospitalization and at discharge was defined by no support of oxygen therapy, low-flux oxygenation (FiO2 ≤50%) and high-flux oxygenation (FiO2 50%).

First-line testing (supplementary table) included all commonly recognized causes of encephalitis according to current guidelines. [13, 16] Brain MRI, standard EEG and CSF analyses were performed in all patients if no contraindicated from general medical conditions. Only patients with full data available for MRI, EEG and CSF were included in the final analyses. When possible, encephalitis was classified as acute demyelinating encephalomyelitis (ADEM)/acute necrotizing encephalitis (ANE) [16] [17] [18] or limbic encephalitis (LE) [16] based on clinical and instrumental data. [13] A c c e p t e d M a n u s c r i p t 8

Treatment of COVID-19 infection was decided by an infectious disease specialist at each centre and included chloroquine/hydroxycloroquine or antiviral treatment, such as lopinavir/ritonavir 200/50 mg 2 BID, darunavir 800 mg 1 QD + ritonavir 100 mg QD, or darunavir/cobicistat 800/150 mg QD.

Treatment of respiratory insufficiency was managed according to standardized protocols for highflow oxygenation or intensive care unit admission. Specific treatments for encephalitis included i) antibiotic treatment for suspected meningitis ii) antiviral treatment in case of suspected viral encephalitis iii) high-dose steroid treatment and iv) immunoglobulins/plasmapheresis. Modified Rankin Scale (mRS) [19] was administered both at admission and at discharge. Poor outcome was defined as death or severe disability (mRS>4). A "positive response" to specific treatment was defined as an improvement of at least two points on the mRS scale. [19] Statistical analyses Data are presented as mean + standard deviation for continuous variables and number (%) for categorical variables. For subgroup comparisons, we used the Fisher exact test and ANOVA test, when appropriate.

The study network recruited 45 cases of encephalitis starting from February 20 th to May 31 st 2020. Of these, 32 cases were affected by SARS-CoV-2 virus infection. The remaining 13 SARS-CoV-2 negative patients (7 males and 6 females, mean age 53.2 + 24 years) were Table 1) .

Onset of neurological symptoms was concomitant with COVID-19 symptomatology in 11 (44%) cases while in 12 cases (48%) neurological onset followed COVID-19 symptoms with a median of 8 (IQR 5 -12) days. In 2 cases neurological symptoms preceded the onset of COVID-19 symptoms after 3 and 5

A c c e p t e d M a n u s c r i p t 10 

At onset, the most common symptoms were delirium/altered mental status (n=17, 68%), aphasia/dysarthria (n=6, 24%) and seizures (n=6, 24%) (Tables 2 and 3) .

During the disease course a total of 9 patients (36%) showed aphasia, 8 (32%) had dysarthria and 6 cases (24%) exhibited focal motor deficits. Seizures were detected in nine patients of whom four developed a focal status epilepticus. Only one patient developed a parkinsonian syndrome. Headache was reported at onset in 6 patients (24%) and by a total of 10 patients (40%) during the disease course. Two patients had a previous diagnosis of stroke, one of mental retardation (with no structural brain abnormalities) and one patient had a previous (2019) diagnosis of possible encephalitis and Behçet disease (negative testing for autoantibodies in serum and CSF and imaging not suggestive for neuro-Behçet). Twelve patients had a diagnosis of hypertension, 6 of dyslipidaemia and 4 of diabetes mellitus.

EEG was abnormal in all cases, showing in most cases a generalized slowing especially localized to frontal derivation (64%), while focal epileptic alteration was observed in six cases (24%). Table 1 ). Fourteen patients underwent CSF RT-PCR for SARS-CoV-2 and all cases were negative (in 5 patients repeated in a second CSF analyses).

Thyroid function and metabolic/infectious screening (supplementary table 1) was normal in all patients. Thirteen patients suspected for autoimmune encephalitis resulted negative for CSF A c c e p t e d M a n u s c r i p t 11 antibodies to intracellular, synaptic, or surface antigens (Euroimmun kit, Luebeck, Germany -see Supplementary Table 1 for details).

As shown in tables 1 and 2 and figure 1, 13 patients (52%) had a normal MRI (E-MRI-), 5 (20%) patients showed specific MRI alterations (ADEM n=1, ANE with positive SWI sequences n=2 and LE n=2), whereas 7 (28%) patients showed heterogeneous MRI alterations (E-MRI+) such as multiple subcortical T2-hyperintensities (n=4), focal cortical T2 and DWI hyperintensities (n=3) and leptomeningeal enhancement (n=1).

All ADEM and LE cases occurred after the onset of COVID-19 symptoms with a delayed neurological onset compared with the remaining encephalitis cases. COVID-19 respiratory involvement was significantly more severe in ADEM/ANE and LE compared to other encephalitis (Table 1 ).

Blood and CSF analyses did not differ between encephalitis' subgroups but higher LDH levels were found in ADEM and LE cases (p=0.001, supplementary Table 2) . Clinical presentation at onset and during the hospitalisation were similar between groups, but a higher frequency of seizures was observed in E-MRI+ cases ( Table 2) . The final clinical outcome was worse in ADEM/ANE and E-MRI+ cases compared to LE and E-MRI-encephalitis (p=0.03, Figure 2 ). Four cases deceased, namely 3 E-MRI+ and one E-MRI-.

In this multicentre study, SARS-CoV-2 infection was associated with a wide clinical spectrum of encephalitis, characterised by heterogeneous clinical presentation and outcomes, thus underlying divergent pathophysiological mechanisms.

The cohort included 25 cases of encephalitis diagnosed according to standard guidelines [13] with confirmed SARS-CoV-2 respiratory infection and full CSF, EEG, MRI available data, recruited in a network involving 13 centres in Lombardy and Veneto, Italy. In order to focus on encephalitis subtypes and outcomes, the study exclude COVID-19 cases with cerebrovascular disease, despite they were the most common neurological presentation of SARS-CoV-2 infection at emergency Department . [20] The large majority of patients with encephalitis exhibited moderate respiratory COVID-19 disease, with prominent neurological disturbances including delirium and aphasia/dysarthria as most common symptoms at onset. Seizures were reported in about a third of patients during disease course with few cases developing status epilepticus, in line with presentation of encephalitis reported in large multicentre studies. [21, 22] The CSF analyses showed mild pleocytosis and/or hyperproteinorrachia in two-third of cases though viral and bacterial screening was negative in all patients. Nineteen CSF specimens resulted negative for SARS-CoV-2 virus using RT-PCR technique, unfortunately not available for the whole sample.

To date, only two cases of encephalitis reported the presence of SARS-COV-2 in CSF, despite negative peripheral and respiratory findings (supplementary Table 3 ), whereas similar viral agents such as SARS-CoV have been associated with rare cases of CNS invasion [23] [24] [25] A c c e p t e d M a n u s c r i p t 13 It should be remarked that the absence of virus in CSF could not definitely exclude a direct viral invasion, as demonstrated for other infectious diseases such as West Nile virus or enterovirus infections. [13] However, the clinical courses and CSF alterations in this series of patients argue against a direct CNS damage and conversely claim for neuroinflammatory and, in rarer cases, autoimmune responses as major players in COVID-19 encephalitis.

This hypothesis was further supported by the cases-classification based on MRI findings. In fact, the majority of patients exhibited normal imaging or heterogeneous T2-hyperintensities in cortical/subcortical areas, mostly associated with seizures and status epilepticus [26] . Further, we identified three cases of ADEM and two cases of LE, thus supporting an immune-mediatedmechanism.

Acute disseminated encephalomyelitis has been already reported after several viral infections, including SARS-COV, MERS-COV [24] and SARS-CoV-2. [27] In our study, two patients presented with the acute necrotising encephalitis (ANE), a severe post-infectious paediatric complication -reported in few SARS-CoV-2 cases so far. [28] Two additionally cases showed typical MRI findings consistent with limbic encephalitis, known to be associated in the majority of cases with autoimmune or paraneoplastic diseases, [13] despite we did not find any known specific antibodies in biofluids. [16] The onset of ADEM/LE cases was delayed after the onset of COVID-19 symptoms, that were more severe in terms of respiratory function compared to other encephalitis. Immuno-modulatory treatment indeed showed high efficacy in the typical ADEM and LE cases, while ANE presented more severe final outcomes-mostly related to known haemorrhagic complications. [18] The other twenty cases of encephalitis occurred almost concomitantly to SARS-CoV-2 respiratory infections, in the majority of cases few days after the onset of COVID-19 symptoms. Two-thirds exhibited negative MRI with CSF abnormalities, in line with cases described for SARS-COV2, [4, 5, 7, 11] but also for SARS-CoV [23] and MERS-CoV infections. [11, 24] We also observed a subset of patients with heterogeneous MRI alterations. These patients showed similar clinical onset and presentations A c c e p t e d M a n u s c r i p t 14 to other phenotypes though they displayed higher prevalence of epileptic seizures. The close timerelationship with SARS-CoV2 infection in these cases argues for a CNS involvement via inflammatorymediated mechanisms. Recent reports claimed for a cytokine-mediated neuroinflammation in COVID-19 encephalitis, [29] as an increased IL-8/TNF-alpha in CSF was observed in one patient with negative MRI findings [6] and two cases with temporal lobe/splenium abnormalities. [30] especially those with negative MRI findings. This is in line with different degree of neurotoxicity of cytokineinduced syndrome observed after immune effector cell-associated treatments. [31] Better response to treatment and final outcome was indeed reported in patients with negative neuroimaging compared to patients with MRI alterations, who in turn exhibited a higher mortality rate.

The wide spectrum of clinical presentation of encephalitis in patients with SARS-CoV2 respiratory infection is similar with phenotypes already associated with influenza and other coronavirus. [11, 23, 24, 27, 32] The neurological complications of influenza, however, have an estimated incidence between 0.21 and 12 cases per million and affects especially children. We acknowledge that this study entails several limitations. First, due to the absence of autopsy or SARS-CoV-2 evidence in CSF, our cases can be classified as "probably associated" with SARS-CoV-2 infection [11] and further studies on CSF using recently-developed intrathecal antibodies are urgently needed. Second, the study might have underestimated the total number of cases, especially severe cases who could not undergo MRI, EEG and CSF assessment, likely due to the prominent respiratory insufficiency with early intubation and/or death. Third, the extensive panel of paraneoplastic/autoimmune encephalitis was not performed in about a third of patients exhibiting transitory symptomatology albeit MRI/CSF was not suggestive for immune disorders. Despite these limitations, this is the first large multicentre study including the highest number of SARS-CoV-2 cases fulfilling criteria for encephalitis so far. [13] Conclusions SARS-CoV-2 infection is associated with a wide spectrum of encephalitis. The majority of cases were concomitant to SARS-CoV-2 infection with findings arguing for a cytokine-mediated CNS-specific involvement. The few cases of ADEM/ LE syndromes, characterized by a delayed in onset and more severe respiratory distress, were likely linked to immuno-mediated mechanisms.

Further studies focusing on biomarkers are needed in order to disentangle the pathophysiological mechanisms underlying the wide spectrum of CNS involvement in COVID-19 disease and to find the best management strategies for this worldwide growing condition. A c c e p t e d M a n u s c r i p t 27 

Olfactory and Gustatory Dysfunctions as a Clinical Presentation of Mild-To-Moderate Forms of the Coronavirus Disease (COVID-19): A Multicenter European Study

Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China

Clinical characteristics and outcomes of inpatients with neurological disease and COVID-Neurology

Plasmapheresis Treatment in COVID-19-related Autoimmune Meningoencephalitis: Case Series

Neurologic Features in Severe SARS-CoV-2 Infection

Steroid-responsive encephalitis in COVID-19 disease

Two patients with acute meningoencephalitis concomitant to SARS-CoV-2 infection

Neurological manifestations of the coronavirus

CoV-2) pandemic 2019-2020

Neurological manifestations associated with COVID19: a review and a call for action

Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System? Viruses

Neurological Associations of COVID-19

Coronavirus

Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy

A clinical approach to diagnosis of autoimmune encephalitis

Acute Disseminated Encephalomyelitis: Updates on an

Acute Necrotizing Encephalopathy of Childhood: Correlation of MR Findings and Clinical Outcome AJNR

Improving the Assessment of Outcomes in Stroke: Use of a Structured Interview to Assign Grades on the Modified Rankin Scale

COVID-19 impact on consecutive neurological patients admitted to the emergency department medRxiv 2020.05.23

UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group Causes of Encephalitis and Differences in Their Clinical Presentations in England: A Multicentre, Population-Based Prospective Study

Symptoms, Risk Factors, and Outcomes of Autoimmune Encephalitis After Herpes Simplex Encephalitis: A Prospective Observational Study and Retrospective Analysis

Possible central nervous system infection by SARS coronavirus

Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV)

A First Case of Meningitis/Encephalitis Associated With SARS-Coronavirus-2

Peri-ictal magnetic resonance imaging in status epilepticus: Temporal relationship and prognostic value in 60 patients

COVID-19-Associated Acute Disseminated Encephalomyelitis -A Case Report

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression

Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease

Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia

Acute Influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis

We would like to express our gratitude to the nurses, auxiliary staff, technicians and all the colleagues who collaborated for the management of patients during the COVID-19 outbreak. 

A c c e p t e d M a n u s c r i p t 17 A c c e p t e d M a n u s c r i p t 28 19.9 Pleocytosis, n (%) 9 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 33 Figure 2